RESUMO
The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been endangering worldwide public health and economy. SARS-CoV-2 infects a variety of tissues where the known receptor ACE2 is low or almost absent, suggesting the existence of alternative pathways for virus entry. Here, we performed a genome-wide barcoded-CRISPRa screen to identify novel host factors that enable SARS-CoV-2 infection. In addition to known host proteins, i.e. ACE2, TMPRSS2 and NRP1, we identified multiple host components, among which LDLRAD3, TMEM30A and CLEC4G were confirmed as functional receptors for SARS-CoV-2. All these membrane proteins bind directly to spikes N-terminal domain (NTD). Their essential and physiological roles have all been confirmed in either neuron or liver cells. In particular, LDLRAD3 and CLEC4G mediate SARS-CoV-2 entry and infection in a fashion independent of ACE2. The identification of the novel receptors and entry mechanisms could advance our understanding of the multiorgan tropism of SARS-CoV-2, and may shed light on the development of the therapeutic countermeasures against COVID-19.
RESUMO
OBJECTIVE:To provide reference for the establishment of prevention and control measures for medication errors. METHODS:Based on JCI standard,51 cases of medication error reported by ADE information platform of our hospital in 2012 were summarized,and analyzed in terms of error type,error time,working life of responsible person,etc. The prevention and con-trol strategies were introduced. RESULTS:Referring to related requirements of JCI standard,medication errors reduced significant-ly during 2013-2014 through personnel training and education,system improvement and process optimization. CONCLUSIONS:Medication errors surveillance and control is important for the promotion of rational use of drugs. JCI standard has played an impor-tant role in monitoring and preventing medication errors.
